Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised Study of CHOP-R in Combination With Acalabrutinib Compared to CHOP-R in Patients With Newly Diagnosed Richter's Syndrome and a Platform for Initial Investigations Into Activity of Novel Treatments in Relapsed/Refractory and Newly Diagnosed Richter's Syndrome.

NCT03899337 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT03899337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03899337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised Study of CHOP-R in Combination With Acalabrutinib Compared to CHOP-R in Patients With Newly Diagnosed Richter's Syndrome and a Platform for Initial Investigations Into Activity of Novel Treatments in Relapsed/Refractory and Newly Diagnosed Richter's Syndrome.
Lead sponsor
University of Birmingham
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 23, 2019
Completion date
July 31, 2028
Enrollment
72 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

richter syndrome